2024
Neuromuscular manifestations of wild type transthyretin amyloidosis: a review and single center’s experience
Živković S, Lacomis D, Soman P. Neuromuscular manifestations of wild type transthyretin amyloidosis: a review and single center’s experience. Frontiers In Cardiovascular Medicine 2024, 11: 1345608. PMID: 38410247, PMCID: PMC10894993, DOI: 10.3389/fcvm.2024.1345608.Peer-Reviewed Original ResearchATTRwt patientsPeripheral neuropathyPrevalence of peripheral neuropathySuspected peripheral neuropathyCases of neuropathyDistal sensory lossTransthyretin amyloid depositionCardiomyopathy patientsClinical featuresTransthyretin genotypingMusculoskeletal manifestationsNeuropathy symptomsATTRwtTransthyretin amyloidosisElderly patientsHeart failureTransthyretin mutationFrequent comorbiditiesMultiple potential causesNeuropathySensory lossElderly menPatientsSenile amyloidosisPeripheral nerves
2022
Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values
Arends S, Drenthen J, van den Bergh P, Franssen H, Hadden R, Islam B, Kuwabara S, Reisin R, Shahrizaila N, Amino H, Antonini G, Attarian S, Balducci C, Barroso F, Bertorini T, Binda D, Brannagan T, Buermann J, Casasnovas C, Cavaletti G, Chao C, Dimachkie M, Fulgenzi E, Galassi G, Gutiérrez G, Harbo T, Hartung H, Hsieh S, Kiers L, Lehmann H, Manganelli F, Marfia G, Mataluni G, Pardo J, Péréon Y, Rajabally Y, Santoro L, Sekiguchi Y, Stein B, Stettner M, Uncini A, Verboon C, Verhamme C, Vytopil M, Waheed W, Wang M, Zivkovic S, Jacobs B, Cornblath D, consortium T, Addington J, Ajroud-Driss S, Andersen H, Antonini G, Attarian S, Badrising U, Balloy G, Barroso F, Bateman K, Bella I, Benedetti L, van den Bergh P, Bertorini T, Bhavaraju-Sanka R, Bianco M, Brannagan T, Briani C, Buerrmann, Busby M, Butterworth S, Casasnovas C, Cavaletti G, Chao C, Chavada G, Chen S, Claeys K, Conti M, Cornblath D, Cosgrove J, Dalakas M, van Damme P, Dardiotis E, Davidson A, Derejko M, van Dijk G, Dimachkie M, van Doorn P, de la Cour C, Echaniz-Laguna A, Eftimov F, Faber C, Fazio R, Feasby T, Fokke C, Fujioka T, Fulgenzi E, Galassi G, Garcia-Sobrino T, Garssen M, Gijsbers C, Gilchrist J, Gilhuis H, Goldstein J, Gorson K, Goyal N, Granit V, Grisanti S, Gutiérrez-Gutiérrez, Gutmann L, Hadden R, Harbo T, Hartung H, Holbech J, Holt J, Hsieh S, Htut M, Hughes R, Illa I, Islam B, Islam Z, Jacobs B, Fehmi J, Jellema K, Pascual I, Kaida K, Karafiath S, Katzberg H, Khoshnoodi M, Kiers L, Kimpinski K, Kleyweg R, Kokubun N, Kolb N, van Koningsveld R, van der Kooi A, Kramers J, Kuitwaard K, Kusunoki S, Kuwabara S, Kwan J, Ladha S, Lassen L, Lawson V, Lehmann H, Pan E, Lunn M, Manji H, Marfia G, Infante C, Martin-Aguilar L, Hernandez E, Mataluni G, Mattiazi M, McDermott C, Meekins G, Miller J, Mohammad Q, Monges M, de la Tassa G, Nascimbene C, Navacerrada-Barrero F, Nobile-Orazio E, Nowak R, Orizaola P, Osei-Bonsu M, Pardal A, Pardo J, Pascuzzi R, Péréon Y, Pulley M, Querol L, Reddel S, van der Ree T, Reisin R, Rinaldi S, Roberts R, Rojas-Marcos I, Rudnicki, Sachs G, Samijn J, Santoro L, Schenone A, Tous M, Shahrizaila N, Sheikh K, Silvestri N, Sindrup S, Sommer C, Stein B, Song Y, Stino A, Tankisi H, Tannemaat M, Twydell P, Vélez-Santamaria P, Varrato J, Vermeij F, Visser L, Vytopil M, Waheed W, Walgaard C, Wang Y, Willison H, Wirtz P, Yamagishi Y, Zhou L, Zivkovic S. Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values. Clinical Neurophysiology 2022, 138: 231-240. PMID: 35078730, DOI: 10.1016/j.clinph.2021.12.014.Peer-Reviewed Original Research
2020
TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients
Moshe-Lilie O, Dimitrova D, Heitner S, Brannagan T, Zivkovic S, Hanna M, Masri A, Polydefkis M, Berk J, Gertz M, Karam C. TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients. Amyloid 2020, 27: 250-253. PMID: 32578459, DOI: 10.1080/13506129.2020.1784134.Peer-Reviewed Original ResearchConceptsHereditary transthyretin (TTR) amyloidosisGene silencing therapySilencing therapyMedian duration of therapyPatients stopped treatmentDuration of therapyATTR amyloidosis patientsBone marrow functionNeuropathy Impairment ScoreATTR amyloid depositsOrthotopic liver transplantationTTR gene silencingMedian durationMarrow functionMedian ageAmyloidosis patientsDiscontinued treatmentFrequent complicationMedian timeLiver rejectionLiver transplantationTreatment optionsDisease progressionGene silencing agentsPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply